Also known as: late-stage pancreatic cancer
Pancreatic cancer is a highly lethal malignancy, most commonly pancreatic ductal adenocarcinoma, often diagnosed late because early symptoms are nonspecific.
Merck and Moderna's personalized mRNA cancer vaccine combined with Keytruda significantly reduced melanoma recurrence risk in a Phase 3 trial. The FDA has not yet approved the vaccine, with potential availability expected by early 2027.
ASTRO issued updated pancreatic cancer radiation therapy guidelines covering resectable, locally advanced, recurrent, metastatic and palliative disease. The revision replaces 2019 recommendations and supports IMRT, daily image guidance, and respiratory motion assessment.
Johnson & Johnson agreed to buy Firefly Bio for $1 billion to advance KRAS-targeted cancer therapies. The company also announced a $1 billion cell therapy manufacturing plant in Pennsylvania as part of a $55 billion US investment plan.
Recent studies have uncovered new cancer therapeutic targets and strategies, including self-assembling antibody-drug conjugates, a dual-action metabolic drug, and a BRAF protein structure. Research also advanced on dendritic cell vaccines, the origins of a rare childhood leukemia, and cancer cachexia treatment.
Pilot genetic testing at ESMO Breast Cancer 2026 found inherited variants in 8.6% of breast and 10.1% of ovarian cancer survivors. A systematic review linked mammographic surveillance to a 50% lower mortality risk.
The FDA granted Fast Track designation to Oncolytics Biotech's pelareorep combined with a checkpoint inhibitor for advanced squamous cell carcinoma of the anal canal. The designation follows encouraging GOBLET study data and supports development in an estimated $1 billion market with no approved therapies.
Preclinical studies reveal that fructose promotes metastasis in ovarian cancer by reducing cell adhesion, while brigatinib enhances PARP inhibitor efficacy by blocking an early adaptive resistance mechanism. The findings suggest dietary modifications and repurposing a lung cancer drug could improve outcomes for high-grade serous ovarian cancer patients.
New studies reveal how cancer cells survive chemotherapy: fructose promotes ovarian cancer spread, platinum-treated 'zombie cells' release TGFβ in lung and ovarian cancers, and mitochondrial metabolism drives 5FU resistance in colorectal cancer. The findings point to potential combination therapy targets.
Lantern Pharma's LP-284 received FDA Orphan Drug Designation for soft tissue sarcomas, while the USPTO allowed a patent for biomarker-guided use of LP-184 in multiple cancers. LP-284 showed a complete metabolic response in a Phase 1 DLBCL patient, and LP-184 demonstrated a 45% disease control rate in advanced solid tumors.
UNM Comprehensive Cancer Center installs MRI-LINAC, enabling real-time tumor tracking and adaptive radiation therapy. The system has treated 10 patients and improves precision, reducing damage to healthy tissue.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07773363 |
Retlirafusp Alfa Plus Apatinib and Chemotherapy as Second-Line Treatment for Pancreatic Cancer |
NOT_YET_RECRUITING | PHASE2 |
| NCT07772258 |
Wearable-Supported Prehabilitation and Rehabilitation for Patients Undergoing Surgery for Pancreatic Cancer |
NOT_YET_RECRUITING | NA |
| NCT07763301 |
YMN-136 Vaccine for Patients With Advanced Hepatobiliary and Pancreatic Malignancies |
RECRUITING | PHASE1 |
| NCT07762950 |
Blood Biomarkers and Gut Microbiota for Pancreatic Cancer Risk in Chronic Pancreatitis |
NOT_YET_RECRUITING | |
| NCT07760012 |
68Ga-SorB PET/CT Imaging in Patients With Solid Tumors |
RECRUITING | NA |
| NCT07756281 |
First in Human Study of SNV1521 With a RAS Inhibitor for People With Advanced Pancreatic Cancer |
NOT_YET_RECRUITING | PHASE1 |
| NCT07752875 |
A Study of LG00313112 in Participants With Advanced Solid Malignancies Harboring a TP53 Y220C Mutation |
NOT_YET_RECRUITING | PHASE1/PHASE2 |
| NCT07737171 |
Safety and Efficacy of Endoscopic Ultrasound (EUS) Guided Radiofrequency Ablation (RFA) in the Treatment of Pancreatic Lesions |
RECRUITING | |
| NCT07736612 |
A Pan-RAS Inhibitor in Combination With Anti-Tumor Therapy in Participants With Advanced Pancreatic Cancer |
NOT_YET_RECRUITING | PHASE1/PHASE2 |
| NCT07713823 |
Study on the Construction and Application of a Large Model Corpus for Pancreatic Cancer Based on Real Clinical Cases |
NOT_YET_RECRUITING |
